Background. L-phenylalanine mustard (LPAM) has been the standard for use in regional chemotherapy (RC) for unresectable in-transit melanoma. Preclinical data demonstrated that regional temozolomide (TMZ) may be more effective. Methods. Patients with AJCC Stage IIIB or IIIC extremity melanoma who failed previous LPAM-based RC were treated with TMZ via isolated limb infusion (ILI) according to a modified accelerated titration design. Drug pharmacokinetic (PK) analysis, tumor gene expression, methylation status of the O 6 -methylguanine methyltransferase (MGMT) promoter, and MGMT expression were evaluated. Primary objectives were to (1) determine doselimiting toxicities (DLTs) and maximum tolerated dose (MTD) of TMZ via ILI and (2) explore biomarker correlates of response.
Results. 28 patients completed treatment over 2.5 years at 3 institutions. 19 patients were treated at the MTD defined as 3,200 mg/m 2 [multiplied by 0.09 (arm), 0.18 (leg)]. Two of five patients had DLTs at the 3,600 mg/m 2 level while only grade 1 (n = 15) and grade 2 (n = 4) clinical toxicities occurred at the MTD. At 3-month post-ILI, 10.5 % (2/ 19) had CR, 5.3 % (1/19) had PR, 15.8 % (3/19) had SD, and 68.4 % (13/19) had PD. Neither PK parameters of TMZ nor MGMT levels were associated with response or toxicity. Conclusion. In this first ever use of intra-arterial TMZ in ILI for melanoma, the MTD was determined. While we could not define a marker for TMZ response, the minimal toxicity of TMZ ILI may allow for repeated treatments to increase the response rate as well as clarify the role of MGMT expression.
BACKGROUND
Regional chemotherapy in the form of hyperthermic isolated limb perfusion (HILP) or its minimally invasive counterpart, isolated limb infusion (ILI), allows delivery of a drug dose to tumor that is 10 to 15 times greater than can be achieved with systemic therapy. Although several different drugs have been evaluated, none has produced the same degree of response, both in magnitude and duration, compared to L-phenylalanine mustard (LPAM) for the treatment of unresectable in-transit melanoma. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Whereas LPAM HILP has been reported to have complete response (CR) rates in the 50 to 80 % range, a multicenter retrospective study of LPAM via ILI found the CR rate to be approximately 30 %. [6] [7] [8] [9] However the rate of severe toxicity requiring amputation (0.3 %) from ILI was 7-fold less than historically reported with HILP (2 %). 8, 9 Although the 30 % CR rate observed after ILI is generally higher than can be achieved with other therapies, the majority of patients will require additional therapy in attempts to eradicate persistent disease. Therefore, there is a need for more effective and durable therapies that can be administered to appropriately selected patients with the goal to maximize response.
Temozolomide (TMZ) is an oral DNA-methylating agent that has been used systemically to treat metastatic melanoma with relatively little toxicity but with clinical response rates of only 15 to 20 %. [11] [12] [13] In preclinical studies using an animal model of advanced extremity melanoma for several melanoma xenografts, we demonstrated that regional chemotherapy with an intra-arterial formulation of TMZ was more effective than systemic TMZ and comparable to regional LPAM.
14 Further analysis suggested that regional therapy with TMZ was more effective when compared with LPAM for xenografts with the low O 6 -methylguanine-DNA methyltransferase (MGMT) activity, whereas LPAM was more effective than TMZ in xenografts with high MGMT activity. 15 This observation suggested that MGMT activity may be useful in predicting the efficacy of TMZ-based regional therapy for advanced extremity melanoma tumors. The primary objectives of this trial were to determine the dose-limiting and non-dose-limiting toxicities of intra-arterial TMZ treatment and to determine the maximum tolerated dose (MTD) of intra-arterial administration of TMZ during ILI that can be carried forward into a phase 2 trial.
METHODS

Patient Eligibility
Patients were eligible for study if they were C18 years of age, had histologically confirmed recurrent American Joint Committee on Cancer stage IIIB, IIIC, or IV extremity melanoma, experienced treatment failure or disease recurrence after a previous LPAM-based regional chemotherapy (ILI or HILP), had directly measurable cutaneous disease distal to planned tourniquet placement, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had a palpable pulse in the affected extremity. All patients underwent whole-body positron emission tomography/computed tomography within 6 weeks of ILI to evaluate the presence of macroscopic disease, which would make the patient ineligible for the study. Patients were required to provide informed consent, and the institutional review boards of the participating institutions approved the study.
Study Design
This trial was an open-label, single-arm, multicenter phase 1 study. Dose level selection proceeded according to a modified accelerated titration design. The starting dose of TMZ was 200 mg/m 2 9 0.09 body surface area (BSA) for the upper extremity and 200 mg/m 2 9 0.18 BSA for the lower extremity. ILI was performed as previously described using a rapid infusion of TMZ (2 to 5 min) into the arterial portion of the circuit after the extremity had been warmed to at least 37°C. We planned to enroll one-patient cohorts with dose doubling between cohorts until the first occurrence of a grade 2 adverse event according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. A dose-limiting toxicity was defined as all limb-related, systemicrelated, nonhematologic drug-or procedure-related adverse events of at least grade 3 in severity that occurred up to 15 days after ILI. We planned to enroll approximately 15 patients into the phase 1 dose escalation portion of this trial, with the possible addition of 10 more patients, to achieve our goal of having 20 patients in the MTD.
Assessment of Tumor Response and Toxicity
Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria modified for cutaneous lesions at one time point 3 months after ILI. Toxicity was assessed by CTCAE v4.03.
Pharmacokinetic Evaluations
High-performance liquid chromatography was used to measure TMZ and the active metabolite, 4-amino-5-imidazole-carboxamide (AIC) infusion circuit and systemic concentrations (Schering-Plough Research Institute Protocol LC/MS/MS 073.100). 16 
Quantitative Polymerase Chain Reaction
Tumor biopsy samples were homogenized by using Lysing Matrix A (MP Bio-Medicals, Solon, OH) and a mini bead beater (Biospec Products, Bartlesville, OK). RNA was isolated, cDNA was synthesized, and quantitative polymerase chain reaction (qPCR) was performed as described previously. The qPCR Human Reference Total RNA is a high-quality control for quantitative PCR geneexpression analysis. qPCR Human Reference Total RNA is composed of total RNA from 10 human cell lines with quantities of RNA from the individual cell lines optimized to maximize representation of gene transcripts present in low, medium, and high abundance.
MGMT Methylation Analysis
Genomic DNA (800 ng) was treated with sodium bisulfite using the Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, CA), which converts all unmethylated cytosines to uracils. Methylated cytosine is protected from this conversion. Two microliters of the bisulfite-modified DNA underwent PCR amplification in a 25 ll volume to produce a 253 bp product from a region on chromosome 10 approximately 400 bp upstream of the MGMT transcription start site using a predesigned assay (PyroMark CpG Assay PM00149702; Qiagen; Valencia, CA) and the PyroMark PCR Kit (Qiagen). Methylation was averaged across the seven CpG sites, and the average of the replicate runs was used for analysis. The average standard deviation across replicate runs was 0.26 (range, 0.09-0.68).
Definitions
The MTD was defined as the dose level below the maximally administered dose at which two or more patients experienced dose-limiting toxicities (DLTs). Time to in-field extremity progression was defined as the time from the date of ILI to the date of in-field extremity progression; the time to progression distribution was compared to that of our historical LPAM treated patients with the logrank test.
RESULTS
Twenty-eight patients completed treatment at three institutions over 2.5 years. Patient characteristics and procedural variables are shown in Tables 1 and 2 . Notably, once the MTD was determined, an amendment allowed patients who had not yet undergone any regional chemotherapy treatments to be treated. ILI was performed successfully in all but one patient in whom ILI catheters could not be placed as a result of small venous vessel size related to a previous deep vein thrombosis from a prior HILP. One patient underwent TMZ ILI but was subsequently removed from the study after determination that the patient had not met study inclusion criteria. Table 3 .
Response by cohort on the basis of measured size changes to target lesions is shown in Fig. 1 . Although optimal response is defined at 3 months, patients with evidence of tumor growth or new histologically confirmed lesions could have a response determination before 3 months and be taken off the study. Of the 19 patients at the MTD, 2 had CR (10.5 %), 1 patient had partial response (5.3 %), 3 patients had stable disease (15.8 %), and 13 patients had progressive disease (68.4 %). At the maximum administered dose (3600 mg/m 2 ), 1 patient had a progressive disease, at 6 weeks while four other patients had stable disease at the 3-month time point. For the 2 patients who experienced CR, 1 patient was free from extremity disease for 18 months before a solitary regional recurrence occurred that was resected. The other patient with CR continues to be free of extremity disease at 18 months. Both patients with CR were free of distant metastatic disease at 18 months. Median time to extremity disease progression for 19 patients at the MTD was 91 days compared to a median time to progression of 111 days (p \ 0.008) for a group of our historical LPAM-treated patients (n = 88) (Fig. 2) . Sixteen patients at the MTD in this trial had undergone prior LPAM based regional chemotherapy; individual patient response to TMZ was different from response to LPAM in 9 (56 %) of 16 patients, as shown in Fig. S1 .
Pharmacokinetic analysis showed higher peak concentrations of TMZ and AIC (metabolite of TMZ) at increasing dose levels, as expected (Fig. 3) . Peak TMZ concentration during ILI, peak AIC concentration, area under the time versus concentration curve for TMZ (data not shown), and the area under the time versus concentration curve for AIC did not appear to correlate with response or toxicity (Fig. 3) . Figure 4 shows MGMT promoter methylation status and qPCR MGMT expression from pre-ILI tumor tissue for patients at the MTD (n = 18) by response. There was no obvious correlation between MGMT promoter methylation status and either MGMT RNA expression or patient response. Likewise, although we did see some variability between patient MGMT RNA expression levels, we did not see a consistent relationship between MGMT levels and tumor response to treatment. Figure 5 shows MGMT expression by response for patients (n = 11) at the MTD who had tumor biopsies performed at multiple time points. MGMT levels were generally stable or decreased when comparing pre-ILI levels to those levels in tumors observed 24 h after ILI or 6 weeks after ILI (Fig. 5) .
DISCUSSION
To our knowledge, this is the first trial to use intraarterial TMZ-based regional chemotherapy for the treatment of advanced extremity melanoma. The MTD for future use in ILI was determined to be 3,200 mg/m 2 times 0.18 for the lower extremity and 0.09 for the upper extremity, and a preliminary CR rate of 10.5 % in 19 patients treated at the MTD was observed. On the basis of genomic analysis of patients whose disease did not respond to LPAM ILI using a TMZ gene signature that included MGMT, we anticipated that about 40 % of this group would be sensitive to TMZ ILI. 17 Although we did have MTD maximum tolerated dose, CPK creatine phosphokinase, MAD maximum administered dose a Serologic toxicity, a grade IV CPK lasting less than 7 days, was not considered a dose-limiting toxicity two patients with CR, several factors may have lowered the response. Notably, conversion of TMZ to the active metabolite is favored by an alkaline environment; during infusion, the limb becomes progressive acidotic, which could have affected drug delivery. 18 Not surprisingly, several patients in this study responded differently to TMZ ILI compared to LPAM ILI (Fig. S1 ), which we also demonstrated in in our preclinical work. Further work is needed as reliable biomarkers that predict patient response have yet to be identified for either LPAM ILI or TMZ. [19] [20] [21] [22] [23] Here the pharmacokinetics of temozolomide and the active metabolite were not predictive of toxicity or response; MGMT expression and MGMT promoter methylation status were explored as a potential predictor of response, with no obvious correlations found. In glioblastomas, MGMT promoter methylation status has been found to be a more sensitive measure of MGMT activity and subsequent responsiveness to alkylating agents. 24, 25 Here MGMT promoter methylation did not correlate with tumor response. Finding correlations was potentially limited by a small number of patients (n = 18) and a modest rate of response to therapy.
By inducing tumor cell death, regional chemotherapy can potentially reduce the ability of the tumor to suppress immune responses and simultaneously prime and activate antigen-specific immune cells for tumor cell killing. 26 TMZ results in the translocation and expression of calreticulin, a signal that encourages dendritic cells to phagocytose and cross-prime tumor antigen-specific T cells. 27 Although monitoring these effects is difficult, the immune response may ultimately explain the differential tumor responses. Type III transforming growth factor (TGF) b receptor expression is down-regulated during progression in many human cancers. 28 Recently, our group demonstrated that plasma type III TGF-b receptor levels were higher in patients whose disease responded to ILI with LPAM and who had significantly improved overall survival. 28 As we start to evaluate the ability of a regional treatment to generate a systemic immune response, combination strategies that use newly approved drugs for melanoma will become important. Trials are currently underway or planned using ILI plus checkpoint blockade inhibitors (Mary S. Brady, personal communication).
Despite the modest objective response rate in this group of predominately pretreated patients, the minimal toxicity of TMZ via ILI allows for additional studies designed to improve the treatments efficacy. Twenty-one percent of our historic LPAM via ILI-treated patients (n = 122) experienced a grade 3 or higher limb toxicity. 6 In this trial, no patient who received the MTD had more than a grade 2 clinical toxicity, and only 7.1 % (2 of 28) of all patients in the trial had grade 3 or higher limb toxicity. Some institutions perform prophylactic fasciotomies at the time of regional chemotherapy to avoid severe toxicity, which may further reduce toxicity, especially in limb perfusion. Another strategy, given the low toxicity, is to explore the use of repeat ILIs with TMZ. Repeat regional treatments with LPAM have been associated with improved response rates but carries increased toxicity, a side effect that may not be as pronounced with TMZ ILI. 29, 30 A second strategy would be to try TMZ use in HILP. HILP appears to be a more effective way to deliver LPAM compared to ILI, but the HILP technique is also associated with a slightly higher toxicity profile. 9 A third approach to improve TMZ ILI response rates might be strategies that involve MGMT inhibition or other pathways involved in drug resistance. 31 Compared to the experience with LPAM ILI, TMZ was well tolerated. TMZ should be continued to be explored for use in regional chemotherapy treatments with the goals of exploring how to better individualize treatment, optimizing regional responses, and determining whether this chemotherapeutic can help facilitate the generation of a systemic immune response to regional therapy.
Disclosure Merck provided funding and drug (temozolomide, TemodarÒ) for this phase 1 clinical trial.
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